This protein carries a human IgG1 Fc tag at the C-terminus. The protein has a calculated MW of 46.7 kDa. The protein migrates as 50-66 kDa under reducing (R) condition (SDS-PAGE).
TNFRSF9
宿主: 人
宿主: HEK-293 Cells
Recombinant
The purity of the protein is greater than 95 % as determined by SDS-PAGE and Coomassie blue staining.
ELISA, FACS
TNFRSF9
宿主: 人
宿主: HEK-293 Cells
Recombinant
>95 % as determined by SDS-PAGE.
Active
限制
仅限研究用
状态
Lyophilized
缓冲液
Tris with Glycine, Arginine and NaCl, pH 7.5
注意事项
Please avoid repeated freeze-thaw cycles.
储存条件
-20 °C
抗原
CD137 (TNFRSF9)
(Tumor Necrosis Factor Receptor Superfamily, Member 9 (TNFRSF9))
别名
4-1BB
背景
4-1BB is also known as CD137, tumor necrosis factor receptor superfamily member 9 (TNFRSF9), induced by lymphocyte activation (ILA), is a co-stimulatory molecule of the tumor necrosis factor (TNF) receptor superfamily. CD137 can be expressed by activated T cells, but to a larger extent on CD8 than on CD4 T cells. In addition, CD137 expression is found on dendritic cells, follicular dendritic cells, natural killer cells, granulocytes and cells of blood vessel walls at sites of inflammation. The best characterized activity of CD137 is its costimulatory activity for activated T cells. Crosslinking of CD137 enhances T cell proliferation, IL-2 secretion survival and cytolytic activity. Further, it can enhance immune activity to eliminate tumors in mice. CD137 can enhance activation-induced T cell apoptosis when triggered by engagement of the TCR/CD3 complex. In addition, 4-1BB/4-1BBL co-stimulatory pathway has been shown to augment secondary CTL responses to several viruses, and meanwhile augment anti-tumor immunity. 4-1BB thus is a promising candidate for immunotherapy of human cancer. CD137 has been shown to interact with TRAF2.